Anika Therapeutics (STU:AKP) EPS (Basic): €-0.68 (TTM As of Mar. 2026)


STU:AKP Anika Therapeutics Inc STU:AKP
63 GF Score
Price €12.80
GF Value €17.96
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Anika Therapeutics EPS (Basic)?

Anika Therapeutics STU:AKP +5.79% 63 EPS (Basic) is €-0.68 as of Mar. 2026. GuruFocus rates STU:AKP with a GF Score™ of 63/100 and a GF Value™ of €17.96 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Anika Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €-0.32. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.68.

Anika Therapeutics's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.32. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.68.

Anika Therapeutics's EPS without NRI for the three months ended in Mar. 2026 was €0.23. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 0.42.

During the past 12 months, Anika Therapeutics's average EPS without NRIGrowth Rate was 2350.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Anika Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 72.40% per year. The lowest was -65.10% per year. And the median was 2.80% per year.

Anika Therapeutics  (STU:AKP) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Anika Therapeutics EPS (Basic) Related Terms

Anika Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Anika Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anika Therapeutics EPS (Basic) Chart

Anika Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 -0.96 -5.17 -3.66 -0.65

Anika Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.31 -0.24 -0.14 0.02 -0.32
STU:AKP
63GF Score
Anika Therapeutics Inc STU:AKP
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anika Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Anika Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-9.292-0)/14.339
=-0.65

Anika Therapeutics's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-4.373-0)/13.531
=-0.32

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-0.68 mean?
Anika Therapeutics (STU:AKP) has a EPS (Basic) of €-0.68 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Anika Therapeutics and its competitors.
Is Anika Therapeutics' EPS (Basic) too high?
Anika Therapeutics' current EPS (Basic) is €-0.68. Overall, Anika Therapeutics has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' EPS (Basic) compare to LFCR and NIKA?
Anika Therapeutics' EPS (Basic) of €-0.68 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Anika Therapeutics and its competitors. Anika Therapeutics's current EPS (Basic) is €-0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (STU:AKP) is currently considered Modestly Undervalued. The stock's GF Value™ is €17.96, compared to a current price of €12.80 — trading 28.7% below its estimated fair value. The current EPS (Basic) is €-0.68. Anika Therapeutics' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Anika Therapeutics (STU:AKP), the current EPS (Basic) is €-0.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anika Therapeutics (STU:AKP) Overvalued in 2026?

Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued. The current stock price of €12.80 is trading 28.7% below its estimated GF Value™ of €17.96. GuruFocus considers Anika Therapeutics to be Modestly Undervalued.

Key valuation signals for STU:AKP:

  • EPS (Basic): €-0.68
  • GF Value™: €17.96 vs. price of €12.80 (28.7% below fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the STU:AKP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Anika Therapeutics Business Description

Other Exchanges ANIK:USA
Address 32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
63GF Score

Get the complete analysis for STU:AKP

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.80
Price
€17.96
GF Value